Information Density: Telix Pharmaceuticals – Signal Evidence & AI Readability

[H2] Leading a new era in radiopharmaceuticals
Telix is a global, commercial-stage biopharmaceutical company focused on the development and commercialisation of therapeutic and diagnostic (‘theranostic’) radiopharmaceuticals. Telix’s extensive pipeline for urologic oncology (prostate and kidney), neuro-oncology (glioma), musculoskeletal oncology (sarcoma) and bone marrow conditioning is underpinned by a strong global supply, manufacturing and distribution network. Telix has received global regulatory approvals from the Australian Therapeutic Goods Administration (TGA), the U.S. Food and Drug Administration (FDA), and Health Canada for its prostate cancer imaging agent and has more than 18 clinical trials underway worldwide. About Telix One of the most expansive, late-stage research portfolios of diagnostic and therapeutic MTR candidates globally. See Pipeline Clinical Pipeline One of the most expansive, late-stage research portfolios of diagnostic and therapeutic MTR candidates globally. See Pipeline   Our lead imaging agent Illuccix®, approved by the FDA and TGA for use in the United States and Australia. Illuccix® and Gozellix® Illuccix® and Gozellix® Our lead imaging agent Illuccix®, approved by the FDA and TGA for use in the United States and Australia. Illuccix® and Gozellix®   Learn more about Telix’s Phase III prostate cancer therapy trial. Learn more ProstACT Global Learn more about Telix’s Phase III prostate cancer therapy trial. Learn more   Latest News See all
[H2] Fighting for Every Day
Courtney Watson is the Director of Programs and Communications at Head for the Cure, a nonprofit organization dedicated to raising awareness and funding for the brain tumor community. Her mother, Sandra was diagnosed with glioblastoma (GBM) in 2016 and passed away the same year — less than nine months after diagnosis. We spoke to Courtney about her family’s journey, the… Read more
[H2] IPAX-2 Study of TLX101-Tx in First-line Glioblastoma Completes Enrolment and Confirms Dosing
Read more
[H2] Telix Announces Collaborations to Explore PSMA-PET Imaging in Emerging Prostate Cancer Treatment Approaches
Read more
[H2] New Publication Demonstrates TLX250-Px (Zircaix®) Potential in Diagnosing Kidney Cancers Beyond ccRCC
Read more

[H2] Advancing precision care
Many existing therapies for cancer and rare diseases are non-selective, impacting healthy tissue and vital organs while treating the disease. Our radiopharmaceuticals are designed to deliver focused doses of radiation with precision targeting via an injection, regardless of where the cancer or disease is in the body. We use a radioactive isotope as a payload, attached to a targeting agent – such as a small molecule or antibody – with an affinity for targeted biomarkers on the surface of cancerous or diseased cells. Depending on the choice of radioisotope payload, either imaging or therapy can be delivered. This specificity of the targeting agent is designed to concentrate radiation at the tumour sites and to limit off-target tissue exposure. Our Technology
[H2] Telix business units
Telix’s business model reflects our focus as a therapeutics-led radiopharmaceutical company committed to precision oncology. The therapeutics unit sits at the core of Telix, leading the Company’s therapeutic pipeline commercialisation and business development. Telix is focused on developing therapies for urologic (prostate and kidney), neurologic (brain) and musculoskeletal (sarcoma) cancers. Therapeutics (Tx) The therapeutics unit sits at the core of Telix, leading the Company’s therapeutic pipeline commercialisation and business development. Telix is focused on developing therapies for urologic (prostate and kidney), neurologic (brain) and musculoskeletal (sarcoma) cancers. The Precision Medicine unit support the Therapeutics unit by enabling the delivery of personalised theranostic solutions to market using Telix’s diagnostics. Diagnostics such as Telix’s approved PSMA-PET/CT imaging agent, Illuccix®, are key to informing treatment decisions and critical to developing and delivering effective therapeutic solutions. Precision Medicine (Px) The Precision Medicine unit support the Therapeutics unit by enabling the delivery of personalised theranostic solutions to market using Telix’s diagnostics. Diagnostics such as Telix’s approved PSMA-PET/CT imaging agent, Illuccix®, are key to informing treatment decisions and critical to developing and delivering effective therapeutic solutions. Medtech provides surgical solutions and digital products that power Telix’s cancer treatment portfolio. This includes the SENSEI® miniature gamma probe for minimally invasive and robotic-assisted surgery, dosimetry software for personalised treatment plans, and artificial intelligence platforms aimed at achieving faster and more accurate diagnoses. Medtech Medtech provides surgical solutions and digital products that power Telix’s cancer treatment portfolio. This includes the SENSEI® miniature gamma probe for minimally invasive and robotic-assisted surgery, dosimetry software for personalised treatment plans, and artificial intelligence platforms aimed at achieving faster and more accurate diagnoses. Telix Manufacturing Solutions is a global network of facilities designed to deliver patient doses worldwide. We are building manufacturing capacity and developing new technologies and processes to allow us to deliver products at scale in a rapidly growing radiopharmaceutical sector. Telix Manufacturing Solutions Telix Manufacturing Solutions is a global network of facilities designed to deliver patient doses worldwide. We are building manufacturing capacity and developing new technologies and processes to allow us to deliver products at scale in a rapidly growing radiopharmaceutical sector.
[H2] Telix Group Companies
Telix is headquartered in Melbourne, Australia with operations in the United States, Europe (Belgium and Switzerland) and Japan. In 2023 we opened our state-of-the-art radiopharmaceutical production facility in Belgium – one of the largest of its kind in Europe. Telix Manufacturing Solutions will deliver significant operational flexibility, research and development capabilities, and support commercial production requirements in Europe and worldwide.
[H2] Disease areas and programs
Telix’s research pipeline aims to address significant unmet medical need in urologic oncology (prostate and kidney), neuro-oncology (glioma), musculoskeletal oncology (sarcoma) and bone marrow conditioning. Read more Prostate Cancer Read more   Read more Kidney Cancer Read more   Read more Brain Cancer Read more   Read more Bone Marrow Conditioning Read more
[H3] Learn more about Telix
Meet our leadership team   Driven by our purpose   Be part of our future

News & Views
[H2] Fighting for Every Day
News, Courtney Watson is the Director of Programs and Communications at Head for the Cure, a nonprofit organization dedicated to raising awareness and funding for the brain tumor community. Her mother,… Read more
[H2] IPAX-2 Study of TLX101-Tx in First-line Glioblastoma Completes Enrolment and Confirms Dosing
News, Telix today announces that the IPAX-2 study[1] of TLX101-Tx (¹³¹I-iodofalan) in patients with newly diagnosed glioblastoma has completed patient enrolment. No dose-limiting toxicities (DLTs) have been observed to date, including… Read more
[H2] Telix Announces Collaborations to Explore PSMA-PET Imaging in Emerging Prostate Cancer Treatment Approaches
News, Telix today announces that it has entered into letters of intent to pursue collaborations with EDAP TMS S.A.(NASDAQ: EDAP, “EDAP”) and Profound Medical Corp. (NASDAQ: PROF, TSX: PRN, “Profound”), leading… Read more
[H2] New Publication Demonstrates TLX250-Px (Zircaix®) Potential in Diagnosing Kidney Cancers Beyond ccRCC
News, Telix today announces the publication of a new independent analysis of Phase 3 ZIRCON trial data in European Urology, demonstrating that TLX250‑Px (Zircaix®, 89Zr-girentuximab) PET/CT imaging may be highly predictive… Read more
[H2] TLX101-Px (Pixlumi®) MAA Accepted in Europe
ASX, News, Telix today announces that the marketing authorization application (MAA) filed in Europe for TLX101-Px (O-(2-[18F]fluoroethyl)-L-tyrosine, 18F-FET), its glioma (brain cancer) imaging candidate, has been validated and accepted for… Read more
[H2] OPTIMAL-PSMA Trial of TLX597-Tx Next Generation RLT Presented at IPCS 2026 Highlighting Therapeutic Potential in Prostate Cancer
News, Telix today announces dosimetry results from the randomized Phase 2 OPTIMAL-PSMA trial of TLX597-Tx in metastatic castration-resistant prostate cancer (mCRPC), presented at the 2026 International Prostate Cancer Symposium (IPCS 2026)… Read more
[H2] Educational Webinar: Unlocking the Potential of PSMA Therapy, A Next‑Generation Portfolio Approach
News, Telix announces an investor webinar exploring the evolution of PSMA-targeted radionuclide therapy and Telix’s differentiated, multi-product approach to treating prostate cancer across the disease… Read more
[H2] ProstACT Global Phase 3 (Part 1) Selected as Late-Breaking Abstract at ASCO 2026
News, Telix today announces that safety and tolerability data from the ProstACT Global Phase 3 study (Part 1) will be presented as a late-breaking oral presentation at the 2026 American Society… Read more
[H2] Notice of Annual General Meeting 2026
ASX, News, Telix announces its Annual General Meeting of shareholders to be held… Read more
[H2] Telix Doses First Patient in Phase 3 IPAX-BrIGHT Trial of TLX101-Tx for Recurrent Glioblastoma
ASX, News, Telix today announces that the first patient has been dosed with TLX101-Tx (¹³¹I-iodofalan) in Telix’s pivotal IPAX BrIGHT trial, marking the first radiopharmaceutical therapy to enter Phase 3 development for glioblastoma,… Read more 1 2 3 … 50

[H2] Radiation has never been more important in cancer care
Radiation has always been a critical part of cancer care, but efficacy has generally been limited in the metastatic setting, while high dosage radiation has come with unwanted side effects. The evolution from external-beam radiation to systemically-delivered and targeted radiation is transforming the use of radiation in cancer care, across the spectrum of diagnostics and staging, to surgical intervention. Telix is developing targeted radiation therapies with the potential to be efficacious as stand-alone treatments or as complements to existing treatment modalities, addressing areas of high unmet medical need. We pair each therapeutic with a diagnostic imaging agent. This underpins the theranostic approach whereby two conjugates are used to target the same cell-surface receptor: one for detection, localisation or staging, and the other for selective destruction of target cancer cells. When used in tandem to plan and execute treatment, and then to assess response and monitor for progression, this approach allows the delivery of truly personalised therapy to patients. Pipeline Clinical Trials
[H2] Illuccix® for prostate cancer imaging
PSMA PET/CT technology is a breakthrough in prostate cancer diagnosis. Illuccix (kit for the preparation of Ga-68 Glu-urea-Lys(ahx)-hbed-CC Injection), also known as 68Ga-PSMA-11 injection), Telix’s lead prostate cancer imaging agent has received U.S. Food and Drug Administration (FDA), Australian Therapeutic Goods Administration (TGA), and Health Canada approval. Approved indications include staging of high-risk patients, identification of suspected recurrence, and selection for PSMA-directed lutetium therapy. Learn more about Illuccix® Find out more Targeted alpha therapy (TAT) Find out more   Find out more Combination therapies Find out more   Find out more Understanding the tumour microenvironment (TME) Find out more   Find out more AI Find out more   Find out more Radio-guided surgery Find out more